We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Greiner Bio-One

Roche Diagnostics

Develops, manufactures, and markets a wide range of in vitro diagnostic systems, instruments, reagents, and tests read more Featured Products: More products

Download Mobile App




Events

ATTENTION: Due to the CORONAVIRUS EPIDEMIC, certain events are being rescheduled for a later date or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
19 May 2020 - 22 May 2020

Serial Procalcitonin Measurements Utilized in Hospitalized Community-Acquired Pneumonia

By LabMedica International staff writers
Posted on 19 Mar 2020
Print article
Image: The Elecsys BRAHMS PCT (procalcitonin) assay is intended for the mortality risk assessment and management of sepsis patients. Featuring a short duration time of only 18 minutes, the Elecsys BRAHMS PCT assay can be easily added to any of the automated cobas immunoanalyzer platforms (Photo courtesy of Roche Diagnostics).
Image: The Elecsys BRAHMS PCT (procalcitonin) assay is intended for the mortality risk assessment and management of sepsis patients. Featuring a short duration time of only 18 minutes, the Elecsys BRAHMS PCT assay can be easily added to any of the automated cobas immunoanalyzer platforms (Photo courtesy of Roche Diagnostics).
Community-acquired pneumonia (CAP) refers to pneumonia (any of several lung diseases) contracted by a person with little contact with the healthcare system. CAP, the most common type of pneumonia, is a leading cause of illness and death worldwide. Its causes include bacteria, viruses, fungi and parasites.

To improve the prognosis of CAP patients, assessment of its severity is important for selecting appropriate antimicrobial agents and site of treatment, whether as an outpatient or in hospital, including a general ward or intensive care unit (ICU). Either CURB-65 or the Pneumonia Severity Index (PSI) is often used to assess the severity of pneumonia because they have been validated to correlate well with prognosis.

Scientists at the Kurashiki Central Hospital (Okayama, Japan) investigated the usefulness of serial procalcitonin (PCT) measurements for predicting the prognosis and treatment efficacy for hospitalized CAP patients. This prospective, multicenter, cohort study enrolled consecutive CAP patients who were hospitalized at 10 hospitals in western Japan from September 2013 to September 2016.

Sputum and blood for cultures and blood for measuring serum antibodies were collected on admission to detect the causative pathogens of CAP. In all hospitals, the serum PCT levels were measured by the Elecsys BRAHMS PCT automated immunoassay (Roche Diagnostics GmbH, Mannheim, Germany), which had a detection limit of 0.02 ng/mL.

The investigators reported that in the 710 patients, 366 microorganisms were identified. The most common causative microorganism was Streptococcus pneumoniae (22.2%), followed by Haemophilus influenzae (11.1%). Both PCT and CRP values on day 1 (D1), D3, and D7 were significantly higher in non-survivors than in survivors. From D1 to D3, the non-survivor group showed increased PCT (PCT D3/D1 > 1) more often than the survivor group, whereas the increase of CRP (CRP D3/D1 >1) was not significantly different. Compared with patients with treatment success, patients with early treatment failure showed significantly higher values of PCT D1, D3, and CRP D3, but similar CRP D1 values.

The authors concluded that to assess prognosis and treatment efficacy in CAP, it would be ideal to measure PCT serially, not only on admission, but again on day 3. If the values of PCT increase from admission to day 3, the antibiotics may need to be changed, or the patients who have deteriorated may require close monitoring. The study was published on March 1, 2020 in the International Journal of Infectious Diseases.

Related Links:
Kurashiki Central Hospital
Roche Diagnostics GmbH



Print article

Channels

Lab Tech.

view channel
Image: Ultra-fast Cycling for Multiplexed Cellular Fluorescence Imaging (Photo courtesy of Massachusetts General Hospital Research Institute).

Ultra-Fast Cycling for Multiplexed Cellular Fluorescence Imaging

In the treatment of tumors, microenvironment plays an important role. It often contains immune cells that are so changed that they promote tumor growth. Until now, analyses of these dynamic changes with... Read more
Copyright © 2000-2020 Globetech Media. All rights reserved.